Kingswood Wealth Advisors LLC Has $411,000 Position in Regeneron Pharmaceuticals, Inc. $REGN

Kingswood Wealth Advisors LLC lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 783 shares of the biopharmaceutical company’s stock after selling 301 shares during the quarter. Kingswood Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $411,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. E Fund Management Hong Kong Co. Ltd. boosted its holdings in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 31 shares during the last quarter. Activest Wealth Management boosted its holdings in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the last quarter. Costello Asset Management INC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Saudi Central Bank purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Finally, Colonial Trust Advisors purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth $32,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on REGN. BMO Capital Markets lifted their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. Sanford C. Bernstein lifted their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Canaccord Genuity Group reiterated a “buy” rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Finally, Jefferies Financial Group lifted their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research note on Wednesday, August 27th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $817.46.

Regeneron Pharmaceuticals Trading Down 0.9%

Shares of Regeneron Pharmaceuticals stock opened at $564.63 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,024.36. The stock’s 50-day simple moving average is $573.95 and its 200 day simple moving average is $565.04. The stock has a market capitalization of $59.85 billion, a P/E ratio of 14.23, a P/E/G ratio of 1.82 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. During the same period in the previous year, the business posted $11.56 EPS. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.